

Pregnancy reports for Revlimid must be sent to Bristol-Myers Squibb (BMS) Medical Information IMMEDIATELY

This form must be returned to BMS Medical Information: Phone: 0800 731 1736, Email: medical.information@bms.com.

NOTE: Please use the first three letters of the month	Date of awareness: DDDMONYYYYY						
Patient Data							
Sex of Patient:							
O Pregnancy of Patient							
O Pregnancy of Patient's Partner OR							
Exposure of a Pregnant Female (complete information below	w)						
Pregnant Woman's Initials (F, M, L):	Date of Birth:	D D M O N Y	Y Y Y Age:				
Patient Initials (F, M, L): (Who received drug)	Date of Birth:	D D M O N Y	/ Y Y Y Age:				
Drug Name:							
Date of First Dose: D D M O N Y Y Y	Y Date of Last Dose:	D D M O N Y	Y Y Y Y				
Pregnancy Initially Diagnosed By:							
O Home Urine Test							
Office Urine Test							
○ Serum Test							
Date of Pregnancy Test: DDMONYYY	Y Last Menstrual Period:		/				
Female is Currently: weeks pregnant OR O No long	ger Pregnant O Unknown						
Female has Elected to: Carry Pregnancy to Term	Expected Date of Delivery:	D D M O N Y	/ Y Y Y				
Terminate Pregnancy	Date Performed or Pending:	D D M O N Y	YYYY				
Reporter's Information:							
Reporter's Name:		Date:	D D M O N Y Y Y				
Reporter's Contact Information/		Reporter's Signature:					
Address: GB							
Northern Ireland		Reporter's Phone Number:					
Reporter's Email Address:		Reporter's Fax Number:					
Patient's Prescribing Physician's Information:							
Physician's Name:		Date:	D D M O N Y Y Y Y				
Physician's Contact		Physician's Signature:					
Information/ Address:		-					
○ GB ○ Northern Ireland		Physician's Phone Number:					
Physician's Email Address:		Physician's Fay Number					

Pregnancy reports for Revlimid must be sent to BMS Medical Information IMMEDIATELY

This form must be returned to BMS Medical Information: Phone: 0800 731 1736, Email: medical.information@bms.com.

Background Information on Reason for Pregnancy		
Was patient erroneously considered not to be of childbearing potential?	O Yes	O No
If yes, state reason for considering not to be of childbearing potential		
Age ≥ 50 years and naturally amenorrhoeic* for ≥ 1 year *amenorrhoea following cancer therapy or during breastfeeding does not rule out childbearing potential	O Yes	O No
Premature ovarian failure confirmed by a specialist gynaecologist	O Yes	O No
Previous bilateral salpingo-oophorectomy, or hysterectomy	O Yes	O No
XY genotype, Turner syndrome, uterine agenesis.	O Yes	O No
ndicate from the list below what contraception was used		
Implant	O Yes	O No
Levonorgestrel-releasing intrauterine system (IUS)	O Yes	O No
Medroxyprogesterone acetate depot	O Yes	O No
Tubal sterilisation (specify below)	O Yes	O No
○ Tubal ligation	O Yes	O No
Tubal diathermy	O Yes	O No
O Tubal chips	O Yes	O No
Sexual intercourse with a vasectomised male partner only; vasectomy must be confirmed by two negative semen analyses	O Yes	O No
Ovulation inhibitory progesterone-only pills (i.e. desogestrel)	O Yes	O No
Other progesterone-only pills	O Yes	O No
Combined oral contraceptive pill	O Yes	O No
Other intra-uterine devices	O Yes	O No
Condoms	O Yes	O No
Cervical cap	O Yes	O No
Sponge	O Yes	O No
Withdrawal	O Yes	O No
Other	O Yes	O No
None	O Yes	O No
ndicate from the list below the reason for contraceptive failure		
Missed oral contraception	O Yes	O No
Other medication or intercurrent illness interacting with oral contraception	O Yes	O No
Identified mishap with barrier method	O Yes	O No
Unknown	O Yes	O No
Had the patient committed to complete and continuous sexual abstinence	O Yes	O No
Was the drug started despite patient already being pregnant?	O Yes	O No
Did patient receive educational materials on the potential risk of teratogenicity?	O Yes	O No
Did patient receive instructions on need to avoid pregnancy?	O Yes	O No

Pregnancy reports for Revlimid must be sent to BMS Medical Information IMMEDIATELY

This form must be returned to BMS Medical Information: Phone: 0800 731 1736, Email: medical.information@bms.com.

NOTE: Please use the first three letters of the month (e.g.: JAN)

Background Information on Reason for Pregnancy														
Prenatal information														
Date of Last Menstrual Period:	D L) M O	N	Y	/ Y	′ Y		Est	imated Delivery D	ate:	D	D M O N	I Y Y	YY
Pregnancy test														
Urine Qualitative	Reference I	Range:								Date:	D	D M O N	I Y Y	YY
Serum Quantitative	Reference I	Range:								Date:	D	D M O N	I Y Y	YY
Past Obstetric History														
Year of Pregnancy Outcome										Gestational	Age '	Type of Deliv	ery	
Y Y Y Y O Spontane	ous abortion	○ There	apeuti	c abo	rtion	C	Live	birth	n Still birth					
Y Y Y Y O Spontane	ous abortion	○ There	apeuti	c abo	rtion	С	Live	birth	n Still birth					
Y Y Y Y O Spontane	ous abortion	○ There	apeuti	c abo	rtion	С	Live	birth	n Still birth					
Y Y Y Y O Spontane	ous abortion	○ There	apeuti	c abo	rtion	С	Live	birth	n Still birth					
Y Y Y Y Y Spontaneous abortion O Therapeutic abortion O Live birth O Still birth														
Birth defects														
Was there any birth defect from a	ny pregnancy	?				C) Ye	S	O No	O Unknown				
Is there any family history of any of	congenital ab	normality	abstin	ence?)	С) Ye	S	O No	O Unknown				
If yes to either of these questi	ons, please	provide d	etails	belo	w:									
Maternal Past Medical His	rtory													
_	•											_		
Condition	Dates				_			4	Treatment		_	Outcome		
	From:		M O	_	Y	Y	Υ Υ	Y						
	To:		M 0		Y	Y	γ	Y	<u> </u>		_			
	From:		M 0 M 0	-	Y	Y	Y	Y						
	From:	D D	МО	N	Υ	Υ	Υ	Υ						
	То:	D D	МО	N	Υ	Υ	Υ	Υ						
	From:	D D	МО	N	Υ	Υ	Υ	Υ						
	То:	D D	МО	N	Υ	Υ	Υ	Υ						
	From:	$\overline{}$	M O		Y	Υ	Y	Y						
	То:	D D	M 0	N	Y	Y	Y	Y						



Pregnancy reports for Revlimid must be sent to BMS Medical Information IMMEDIATELY

This form must be returned to BMS Medical Information: Phone: 0800 731 1736, Email: medical.information@bms.com.

NOTE: Please use the first three letters of the month (e.g.: JAN)

Condition	Fron	From						Trec	atment			
	D	D M C) N	Y	Y	/ N	/					
	D	D M C) N	Y	Y	/ \	/					
	D	D M C) N	Y	Y	/ \	/					
	D	D M C) N	Y	Y	/ \	/					
	D	D M C) N	Y	Y	/ \	/					
	D	D M C) N	Y	Y	/ \	/					
	D	D M C) N	Y	Y	/ \	/					
Maternal Social History												
cohol	O Yes O No To	bacco				() Y∈	25	O No	IV or recreational drug use	O Yes	O No
yes, amount/units per day:	If	yes, amou	nt pe	r day:						If yes, provide details:		
Maternal medication dur	ing pregnancy and ir	n 4 week	s he	fore r	regi	nan	cv					
(including herbal, alternative a									Ind	dication		
	nd over the counter medi	icines and	dieto	ary sup	plem			Y	Ind	dication		
(including herbal, alternative a	nd over the counter medi Dates Start Date:	icines and	dieto) Y	Y Y Y	Inc	dication		
(including herbal, alternative a	nd over the counter medi	icines and	D M	ary sup	plem) Y	Y Y Y Y	Ind Y Y	dication		
(including herbal, alternative a	Dates Start Date: Stop Date/Continu	icines and	D ND N	ary sup	plem) Y	Y Y Y Y Y Y	Inc Y Y Y Y Y	dication		
(including herbal, alternative a	Dates Start Date: Stop Date/Continu	uing: D	D MD MD M	M O O O	N N) Y	Y Y Y Y Y Y Y Y Y	Ind Y Y Y Y	dication		
(including herbal, alternative a	Dates Start Date: Stop Date/Continu Stop Date/Continu	uing: D	D A D A D A D A	M O O O O O O	N N) Y	Y	Inc	dication		
(including herbal, alternative a	Dates Start Date: Start Date: Start Date: Stop Date/Continu Start Date: Stop Date/Continu Start Date:	uing: D	D A D A D A D A	M 0 M 0 M 0 M 0 M 0	N N N) Y	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Inc	dication		
(including herbal, alternative a	Dates Start Date: Stop Date/Continu Start Date: Stop Date/Continu Start Date: Stop Date/Continu Start Date: Stop Date/Continu	uing: D uing: D uing: D	D A D A D A D A D A D A	M 0 M 0 M 0 M 0 M 0 M 0 M 0 M 0 M 0 M 0	N N N N N N) Y	Y	Ind Y Y Y Y Y Y Y Y	dication		
(including herbal, alternative a	Dates Start Date: Stop Date/Continu Start Date:	uing: D uing: D uing: D uing: D	D A A D A A D A A D A A	M O O O O O O O O O O O O O O O O O O O	N N N N N N N N N N N N N N N N N N N) Y	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Inc	dication		
(including herbal, alternative a	Dates Start Date: Stop Date/Continu	uing: D uing: D uing: D uing: D	D A A D A D A A D A D A A D A D A A D A D A A D	M O O O O O O O O O O O O O O O O O O O	N N N N N N N N N N N N N N N N N N N) Y	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Inc Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	dication		
(including herbal, alternative a	Dates Start Date: Stop Date/Continu Start Date:	uing: D uing: D uing: D uing: D uing: D	D	M O O O O O O O O O O O O O O O O O O O	N N N N N N N N N N N N N N N N N N N) Y	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Inc	dication		
Maternal medication dur (including herbal, alternative a Medication/treatment	Dates Start Date: Stop Date/Continu	uing: D uing: D uing: D uing: D uing: D	D	M O O O O O O O O O O O O O O O O O O O	N N N N N N N N N N N N N N N N N N N		Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Inc	dication		
(including herbal, alternative a	Dates Start Date: Stop Date/Continu	uing: D uing: D uing: D uing: D uing: D	D	M O O O O O O O O O O O O O O O O O O O	N N N N N N N N N N N N N N N N N N N		Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	Inc Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y	dication		



Pregnancy reports for Revlimid must be sent to BMS Medical Information IMMEDIATELY

This form must be returned to BMS Medical Information: Phone: 0800 731 1736, Email: medical.information@bms.com.

Data Privacy Notice

Your personal data will be processed by Bristol-Myers Squibb Pharma EEIG (hereinafter "BMS"), as marketing authorisation holder of pharmaceutical products and its worldwide Affiliates, to the extent and for as long as necessary, for the purposes of the compliance with drug safety legal obligations and for storage purposes.

To conduct risk management programme activities, we may use third party service providers, who will handle directly any reporting relating to pregnancy, acting on our behalf, and upon our prior instructions.

BMS may disclose your personal information to regulatory authorities, affiliates of the BMS Group, service providers or other collaborators. Some of these entities may be located outside of the UK. BMS will take appropriate measures, such as implementing standard data protection clauses, to ensure that your personal information will be kept secure in accordance with applicable data protection law. BMS will only retain your personal data for the length of time required by law.

Under applicable law, you may have the right to access and verify your personal information held by BMS, receive a copy of it, obtain its correction and deletion if it is inaccurate and object to certain processing. If you wish to exercise those rights, you can contact our data protection officer at: eudpo@bms.com. You may also have the right to lodge a complaint with the supervisory authority enforcing data protection by visiting this URL: https://ico.org.uk/

Reporter's Signature (required):											
Signature:	Date signed:	D D M O N Y Y Y Y									

On behalf of BMS, thank you for providing information that will assist us in our commitment to patient safety.



This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

